Prospective first-trimester screening for trisomy 21 in 30,564 pregnancies - 18/08/11
Reprint requests: Kypros H. Nicolaides, Harris Birthright Research Centre for Fetal Medicine, King's College Hospital, Denmark Hill, London SE5 9RS, UK.Abstract |
Objective |
This study was undertaken to evaluate the performance of a 1-stop clinic for first-trimester assessment of risk (OSCAR) for trisomy 21 by a combination of maternal age, fetal nuchal translucency (NT) thickness, and maternal serum-free ß- human chorionic gonadotrophin (hCG) and pregnancy-associated plasma protein-A (PAPP-A).
Study design |
OSCAR was carried out in 30,564 pregnancies at 11 to 13+6 weeks. Patient-specific risks for trisomy 21 and detection and false-positive rates were calculated.
Results |
The median maternal age was 34 (range 15-49) years. Chromosomal abnormalities were identified in 330 pregnancies, including 196 cases of trisomy 21. The estimated risk for trisomy 21 was 1 in 300 or greater in 7.5% of the normal pregnancies, in 93.4% of those with trisomy 21 and in 88.8% of those with other chromosomal defects.
Conclusion |
The most effective method of screening for chromosomal defects is by first-trimester fetal NT and maternal serum biochemistry.
Le texte complet de cet article est disponible en PDF.Key words : Trisomy 21, Screening, Nuchal translucency, Serum-free β- human chorionic gonadotrophin and pregnancy-associated plasma protein-A, First trimester
Plan
Vol 192 - N° 6
P. 1761-1767 - juin 2005 Retour au numéro
Article précédent
- Societies
- Overweight and obese in gestational diabetes: The impact on pregnancy outcome
- Oded Langer, Yariv Yogev, Elly M.J. Xenakis, Lois Brustman
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?